Evidence map›Paper›PMID 24551546›Full record

ArticleChemistryOpen2013

Incorporation of Bulky and Cationic Cyclam-Triazole Moieties into Marimastat Can Generate Potent MMP Inhibitory Activity without Inducing Cytotoxicity.

Mingfeng Yu, Ngee H Lim, Samantha Ellis, Hideaki Nagase, James A Triccas, Peter J Rutledge, Matthew H Todd

Abstract read
In one paragraph

Article in ChemistryOpen, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Structure optimization and molecular dynamics studies of new tumor-selectiveJournal of enzyme inhibition and medicinal chemistry · 2024
    Article
  3. Article
  4. A direct method for theBeilstein journal of organic chemistry · 2016
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mingfeng YuSchool of Chemistry, The University of Sydney Sydney, NSW 2006 (Australia).
Ngee H LimThe Kennedy Institute of Rheumatology, University of Oxford 65 Aspenlea Road, London W6 8 LH (United Kingdom).
Samantha EllisSydney Medical School, The University of Sydney Sydney, NSW 2006 (Australia).
Hideaki NagaseThe Kennedy Institute of Rheumatology, University of Oxford 65 Aspenlea Road, London W6 8 LH (United Kingdom).
James A TriccasSydney Medical School, The University of Sydney Sydney, NSW 2006 (Australia).
Peter J RutledgeSchool of Chemistry, The University of Sydney Sydney, NSW 2006 (Australia).
Matthew H ToddSchool of Chemistry, The University of Sydney Sydney, NSW 2006 (Australia).

Funding

TIMP Engineering and Application to ArthritisR01AR040994 · NIAMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI BREW, KEITH · 1991 to 2013
$4.8M
NIAMS NIH HHS R01 AR040994
6 · The paper itself

Abstract

The synthesis and matrix metalloproteinase (MMP) inhibitory activity of a cyclam-marimastat conjugate and its metal complexes are described. The conjugate, synthesized with a copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition ("click" reaction), contains two zinc-binding groups (ZBGs). The metal complexation behavior with copper(II) and zinc(II) was investigated using UV/Vis spectrophotometry and (1)H NMR spectroscopy, respectively, demonstrating that the first equivalent of the metal ion was chelated by the cyclam-triazole moiety rather than the hydroxamic acid site. Thus, the corresponding mononuclear metal-cyclam complexes were successfully prepared with one equivalent of the metal salt. Both the cyclam-marimastat conjugate and its metal complexes exhibited slightly reduced potency against MMP-1, but essentially identical inhibitory activity against MMP-3. The conjugate and its metal complexes displayed little or no cytotoxicity, further supporting their potential suitability for imaging MMP localization and activity. To the best of our knowledge, this is the first report that describes the incorporation of metal complexes into an MMP inhibitor without influencing the preexisting ZBG, and the first report of the evaluation of structures containing more than one ZBG as MMP inhibitors.

Indexed as

biological activityclick chemistrymarimastatmatrix metalloproteinasemetal complexes

Identifiers

PMID24551546
PMCPMC3703814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.